Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (211-220 of 232) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
Cancer Research|May 6, 2004
Proceedings of the Oxygen Homeostasis/Hypoxia MeetingBennett Kaufman, Orit Scharf, Jeffrey Arbeit, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Alain C Mita, Zihan Wei, et al.
British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Pageof 24

Showing results (211-220 of 232) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
Cancer Research|May 6, 2004
Proceedings of the Oxygen Homeostasis/Hypoxia MeetingBennett Kaufman, Orit Scharf, Jeffrey Arbeit, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Alain C Mita, Zihan Wei, et al.
British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Cancer|February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trialMichael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Pageof 24